Recent Blog Articles

Outlook on diabetes drug less than rosy

Updated: August 01, 2007

Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

In May 2007, millions of people with diabetes got something extra to worry about — the possibility that a drug they were taking to control blood sugar might be harming their hearts. According to a report in the New England Journal of Medicine (NEJM) that touched off a media firestorm, Avandia (rosiglitazone) increases the chances of having a heart attack or dying of cardiovascular disease. The news prompted many people to call their doctors.

To continue reading this article, you must log in.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »

I'd like to receive access to Harvard Health Online for only $4.99 a month.

Sign Me Up

Already a member? Login ».


As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.